Needham lowered the firm’s price target on Sarepta (SRPT) to $125 from $183 and keeps a Buy rating on the shares. The company faced significant pressure following earnings, triggered by the ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

Across hundreds of published papers, CBER’s new chief has argued for more stringent measures of assessing drugs for cancer ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...